Abstract: The invention provides a variable gain amplifier system for use in a burst mode receiver, said system comprising an amplifier adapted to amplify a signal; a gain control module; a dc offset compensation module adapted to derive a compensation signal as a function of the amplifier gain. Compared to existing methods for dc offset compensation in variable gain amplifier, the system and method for dc offset compensation allows fast adjustment of rapidly changing dc offsets that occur in applications where the gain of the variable gain amplifier is adjusted rapidly.

Abstract: The invention concerns a human stem cell isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof.

Abstract: A scanning ophthalmoscope focuses coherent light to a target area in which a subject's eye is located. One or more scanning stages direct the light in a scanning pattern within the target area, and an imaging detector receives a reflected light signal returned following retinal reflection in the subject's eye. Adaptive optics compensate for aberrations in the wavefront. The light is provided as an annular beam at a plane which is conjugate with the pupil of a subject whose eye is located in the target area, whereby the annular beam is focused from an annulus at the pupil of the eye to a spot at the fundus of the eye. The spot size resulting from using an annular beam in this way is significantly reduced providing enhanced resolution.

Abstract: A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.

Abstract: A method of producing microparticles having a median diameter up to 100 ?m and the microparticles so produced are described. The method includes the steps of providing a solvent having a bioactive dispersed or dissolved therein and a vehicle dissolved therein, carrying out an emulsification in a non-solvent phase to produce an emulsion containing the bioactive and the vehicle in a solvent phase, and evaporating the solvent to leave the microparticles, wherein a mixture of at least two surfactants is employed to stabilize the emulsion and wherein the mixture has a hydrophilic-lipophilic balance (HLB) of up to 8.

Abstract: The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient.

Abstract: The invention relates to a novel peptide, polypeptide or monoclonal antibody for use in the treatment of conditions characterized by elevated levels of ?-amyloid (A? 39-43 amino acid peptide) in a subject, especially Alzheimer's Disease. The invention particularly relates to an amyloid precursor protein (APP)-binding polypeptide which, when administered outside an APP-expressing cell, reduces the release of A? 39-43 by the cell.

Abstract: Cytotoxic ?? T cells form an essential component in immunity to infections and tumors, and are also implicated in host defense against these challenges. The present disclosure demonstrates the ability of activated ?? T cells to cross-present exogenous antigens to CD8+ ?? T cells, a process previously thought to be mediated best by dendritic cells. In particular, the present disclosure provides a method for cross-presentation of antigen derived from tumor cell or microbial organisms such as viruses, bacteria, yeasts, parasites, and the like, or from cells infected with such organisms, to a CD8+ ?? T cell. Still further, the present disclosure provides a method for treatment of a tumor or a chronic or recurrent infectious disease, comprising delivering an antigen-presenting autologous ?? T cell population above into a patient requiring such treatment. Still yet further, a method is described for preparing a peptide-specific effector T cell.

Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.

Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.

Abstract: The invention provides transistor device comprising a source, a drain and a connecting channel, the channel is a nano-structure device adapted to allow current flow between the source and drain. The channel comprises an ultra-high doping concentration and is of the same polarity as in the source and/or drain. Essentially the transistor device of the present invention acts as a junctionless, highly-doped gated resistor. In the context of optimal performance of the transistor high doping means equal to or exceeds 1×1019 atom/cm3 results in that the device can operate as a junctionless transistor device.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: The invention provides an indazole derivative of formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1, R2, R3 and R4 are as defined herein. The indazole derivatives are capable of blockading voltage dependent sodium channels and they are useful in the treatment or prevention of normal tension glaucoma, multiple sclerosis, a motorneurone disease, stroke, spinal cord injury, Alzheimer's disease, Parkinson's disease or pain.

Abstract: A method (1) of developing software code for executing on a target digital processor uses a memory in which it maintains data structures having elements, each of the elements storing data which is represented by a label, and at least some links between the elements are created by the target processor as data is being processed. The method comprises the step (3) of writing the software code with data structure processing operations which comply with random structure preservation rules (2). A static analysis timing tool automatically parses (4) the code developed in step (2) to identify all operations. It determines (7) from an operation and all possible input states for that operation an average time value for execution of the operation by a target data processor, and stores (9) said average time value. It determines (8) from the operation and all possible input states all possible output states for that operation.

Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?

Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.

Abstract: This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

Abstract: A nano viscometer device suitable for determining the concentration of a solute within a fluid sample preferably includes a hollow core Photonic Crystal Fibre (HC-PCF) acting as a capillary tube having a core and means for filling the capillary tube with a fluid sample. Light is preferably guided light into the HC-PCF and detected exiting the tube. The rate at which the capillary tube is filled with the fluid is optically measured based on the light to determine the viscosity of the fluid to calculate the concentration of a solute. The preferred capillary viscometer is capable of measuring the viscosity of nano-litre quantities of a sample fluid. On one example, the preferred viscometer makes use of HC-PCF for the detection of glucose dissolved in nano water, demonstrating that HC-PCF can be used for continuous monitoring of glucose levels within blood plasma.

Abstract: The present invention provides an apparatus (1) for attaching a prosthetic limb to the bone of a patient, the apparatus comprising a proximal component (2) to mount to a bone implant, a distal component (3) to mount to a prosthetic limb, and a coupling body (4, 5) coupling together the proximal and distal components (2,3) with freedom to articulate when, in use, a bending and/or torsional force is applied to the prosthetic limb, only when the force exceeds a threshold level, whereby the force may be accommodated by articulation within the attachment apparatus (1). The attachment apparatus (1) thus functions as a fail-safe articulation mechanism protecting the bone of the patient.

Abstract: A tunable laser device (1) comprises integrally formed first and second ridge waveguides (5, 6). A longitudinally extending ridge (12) defines first and second light guiding regions (19, 20) of the first and second waveguides (5, 6) A plurality of first and second slots (27, 28) extending laterally in the ridge (12) adjacent the first and second waveguides (5, 6), produce first and second mirror loss spectra of the respective first and second waveguides (5, 6) with minimum peak values at respective first and second wavelength values. The spacing between the second slots (28) is different to that between the first slots (27) so that with one exception the minimum peak values of the first and second mirror loss spectrum occur at different wavelength values. The first and second waveguides (5, 6) are independently pumped with variable currents to selectively vary the common wavelength at which the minimum peak values of the first and second mirror loss spectra occur to produce Vernier tuning of the device.